In STEP 1 and STEP 3, patients on semaglutide lost 14.816.0% BW compared to 2.45.7% in the placebo group at 68 weeks 26,27
The main photoproduct ( N -oxide formed on a side chain) can act as a type I and type II photosensitizer
These findings suggest the potential therapeutic application of GLP-1 in the prevention and treatment of endothelial damage induced by oxidative stress in diabetic patients
Summary: GLP-1 agonists are not specifically licensed to treat leptin resistance, but they promote weight loss through mechanisms that work independently of leptin signalling pathways
The non-enzymatic antioxidants include- ascorbic acid (vitamin C), -tocopherol (vitamin E), carotenoid, thiol antioxidants, flavonoids and metallonin (McCall and Frei 1999)
Fuentes et al., 2014), which has the potential to improve the therapeutic effects of CVD (Smits et al., 2018), and can influence cardiac metabolism as well as improve inflammatory responses in order to reduce clinical symptoms and disease progression in CVD patients
